Processa Pharmaceuticals (NASDAQ:PCSA) is focused on developing drugs that are intended to improve the survival and/or quality of life for patients who have a high unmet medical need. With a keen eye on advancing their portfolio, their projects currently span across various stages of clinical and preclinical development. They aim to leverage their scientific expertise to bring novel therapies to market, specifically targeting conditions that lack effective treatments. Their objectives center on rigorously pushing their research and development pipeline while ensuring safety and efficacy in their therapeutic solutions, ultimately striving to address the significant gaps in patient care.